NIH GUIDE, Volume 22, Number 4, January 29, 1993

RFA:  CA-93-07

P.T. 34


  Clinical Trial 


  Chemotherapeutic Agents 


National Cancer Institute

Letter of Intent Receipt Date:  February 12, 1993

Application Receipt Date:  March 23, 1993

The Division of Cancer Treatment of the National Cancer Institute

would like to clarify Request for Applications (RFA CA-93-07),

published December 18, 1992 as follows:

The Division of Cancer Treatment (DCT), National Cancer Institute

(NCI) invites cooperative agreement (U01) applications from

institutions wishing to perform Phase I trials of promising

anti-cancer agents in patients with cancer refractory to currently

available therapy and to conduct laboratory studies in support of the

clinical trials such that their conduct leads to a greater

understanding of the relationship between drug administration and

biological changes in patients.  In general patients should be

treated only at the applicant institution, although alternative

arrangements will be considered if well justified.  Support for

laboratory studies may be conducted by collaborators at other


The Letter of Intent Receipt date is changed to February 12, 1993.

Under AWARD CRITERIA, the anticipated date of award is corrected to

read December 1, 1993.


Dr. David Parkinson, Chief Investigational Drug Branch

Cancer Therapy Evaluation Program

National Cancer Institute

Executive Plaza North, Room 734

Bethesda, MD  20892

Telephone:  (301) 496-5223

FAX:  (301) 480-4663


Return to 1993 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.